More importantly, a very recent study has identified miR-146a as a comparable immune checkpoint molecule in melanoma, and a miR-146a antagomiR combined with anti-PD-1 enhances the anti-tumor effect of anti-PD-1 therapy, suggesting that miRNAs may be a novel combination target for immune checkpoint therapy (131). This evidence concerns the gene PDCD1 and neoplasm.